Brain & Mind Research Institute (BMRI)

The leading Australian provider of expert clinical assessment, investigation and innovative treatments for common brain and mind disorders.

Key advantages
  • Unique collaboration of basic science, clinical research and clinical service delivery within the one facility.
  • Investigation and treatment of diseases affecting the brain and mind.
  • The translation of research into improved treatment and disease-prevention strategies.


The BMRI provides expertise in four core areas:

  • translational research
  • clinical services
  • basic science
  • brain imaging (at the Ramaciotti Centre).
Translational research

Translational research carried out by BMRI includes chronobiology and sleep studies, ERP, MS clinical trials, group therapy, neuropsychological assessment, cognitive remediation, e-health research and initiatives, and a healthy brain ageing clinic.

Clinical services

Clinical services are provided by BMRI's resident psychiatrists, psychologists, neurologists, general practitioners, and mental health nurses. The BMRI also provides services funded by headspace (Australia's National Youth Mental Health Foundation), including headspace Community Awareness and headspace Community of Youth Services programs.

Basic science

Basic science is carried out by BMRI's specialist laboratories:

  • Neurobiology Laboratory
  • Alzheimer’s and Parkinson’s Disease Laboratory
  • Prion Disease Laboratory
  • Neuroinflammation Laboratory
  • Molecular Neuroscience Laboratory
  • Behavioural laboratories
  • MS Brain Bank
Ramaciotti Centre for Brain Imaging

Ramaciotti Centre for Brain Imaging does human and animal PET scanning, MRIs, and hot cells imaging.

Research and expertise capability

The development of new therapies and preventative techniques through clinical trials is the ultimate aim of most biomedical research. Effective collaboration between academics and the pharmaceutical industry is vital to achieving this goal.

The BMRI is in a unique position, as it provides technology and associated staffing, clinical services, patient base, and expert advice in the one institution. This makes it a valuable resource to pharmaceutical companies and other health-related organisations.

Further opportunities exist for BMRI to build relationships with these industry groups, in order to put its research and clinical capabilities to good use in the development of effective new therapies.


  • Contract imaging studies for the pharmaceutical industry. This includes PET studies of lead compounds in normal animals, animal models, transgenics, human volunteers and patients; tracer kinetic modelling and quantification of pharmocokinetic and/or pharmacodynamic parameters.
  • Specialist clinical imaging studies for patients with complex neurological and psychiatric illnesses.
  • Commercialisation (to industry) of new technologies developed at BMRI, such as imaging technologies, radiopharmaceuticals, new detector technologies, and software/computing algorithms.
  • Contract use of existing models and technologies, eg mouse models.
  • Pay-as-you-learn researchers attending the facility for detailed instruction about clinical or biomedical procedures.

Principal researchers / consultants